D
Aimia Inc. AIM.TO
TSX
Recommendation
Sell
Prev Close
$2.42
Volume
--
Avg Vol (90D)
46,239
Market Cap
$163.94M
Dividend & Yield
--
52-Week Range
$2.28 - $3.83
P/E (TTM)
--
EPS (TTM)
-$1.75
My Lists My Alerts
Report
Rating
Reward
D
Weak
Risk
D
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Fair
Solvency Index
Good
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
8/9/2023 - Globe Newswire
AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions
8/8/2023 - Globe Newswire
AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates
7/18/2023 - Globe Newswire
AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions
7/10/2023 - Globe Newswire
AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series
7/5/2023 - Globe Newswire
AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the American Journal of Cancer Research
6/27/2023 - Globe Newswire
AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
6/27/2023 - Globe Newswire
AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
6/14/2023 - Globe Newswire
AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments
6/12/2023 - Globe Newswire
AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update
5/15/2023 - Globe Newswire
AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast
5/9/2023 - Globe Newswire
Income Statement
Total Revenue (TTM)
$154.05M
EBITDA (TTM)
-$63.84M
EBIT (TTM)
-$79.15M
Net Income (TTM)
-$139.25M
Balance Sheet
Total Assets (Q)
$729.65M
Total Debt (Q)
$132.82M
Total Liabilities (Q)
$288.12M
Book Value Per Share (Q)
$2.75
Cash Flow
Cash from Operations (TTM)
-$8.85M
Cash from Investing (TTM)
-$341.48M
Cash from Financing (TTM)
$62.90M
Net Change in Cash (TTM)
-$294.26M
Filings
Filing Date
Tuesday, March 26, 2024
Period Date
Sunday, December 31, 2023
Next Filing
Week of May 6 and 10 (est)
Price History
Loading...
Beta
0.63
7-Day Total Return
-5.74%
30-Day Total Return
-20.69%
60-Day Total Return
-30.72%
90-Day Total Return
-23.33%
Year to Date Total Return
-24.09%
1-Year Total Return
-34.66%
2-Year Total Return
-55.68%
3-Year Total Return
-53.91%
5-Year Total Return
-44.31%
52-week Low
Apr 18, 2024 - $2.28
52-week High
May 23, 2023 - $3.83
Valuation
Market Cap
$163.94M - Micro Cap
Enterprise Value
$370.71M
Price/Sales (TTM)
1.43
Price/Book (Q)
0.88
Dividends and Shares
Shares Outstanding
90.98M
Dividend Per Share (Most Recent)
$0.20
Dividend Per Share (TTM)
--
Corporate Info
Website
www.aimia.com
Phone Number
647-948-8758
Address
1 University Avenue
Toronto, ON M5J 2P1
Country
Canada
Year Founded
2008
Business Description
Sector
Communication Services
Industry
Media and Entertainment
Aimia Inc. invests in public and private companies. It operates through Bozzetto, Cortland International, and Holdings segments. The company, through its long-term investments, provides specialty... more
Weiss Ratings